Ekso Bionics’ CEO Provides Update on Magnitude of Stroke Rehabilitation Market on CNBC’s “On the Money”
RICHMOND, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Thomas Looby, President and Chief Executive Officer of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company delivering solutions for medical and industrial markets, provided an update on the stroke rehabilitation market. Addressing the stroke market is a unique opportunity for Ekso Bionics to create a new standard of care focusing on issues such as cost of care, safety of care-workers, and length of stay, while simultaneously building a long-term sustainable business model.
The interview, which aired on CNBC’s “On the Money” with Becky Quick, can be viewed here: Ekso on CNBC Becky Quick
“To meet global demands for quality, efficiency and performance, companies around the world continue to integrate robotic technologies into their processes. Healthcare is no exception as robot-assisted surgery has become the standard of care for some procedures. In the area of stroke rehabilitation, there is a need to ignite patient neuroplasticity through repetitive motion and the Ekso GT technology is ideally positioned to meet that demand,” said Thomas Looby, President and Chief Executive Officer of Ekso Bionics.
“Being the first in a new category means charting new territory with limited visibility on the pace of adoption and the ideal mix of sales versus rentals. We believe that we have the best and smartest medical device on the market for our clinical customers with the broadest FDA approval in the industry. We remain confident in our ability to deliver on the promise of expanding the use of robotic exoskeletons across industries. We have clear objectives for our businesses, are closely monitoring key metrics and will aggressively act to course correct as needed,” added Looby.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) estimates or projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
Media Contact: Carrie Yamond 212-867-1788 firstname.lastname@example.org Investor Contact: Debbie Kaster 415-937-5403 email@example.com
Released May 15, 2017